Ravgen Wins $57M Verdict In Genetic-Testing Lawsuit

Reuters (1/16, Brittain) reports, “Genetic-testing company Natera must pay Maryland biotech company Ravgen $57 million in damages for infringing one of Ravgen’s patents, a jury in Austin, Texas, said on Tuesday.” While “the jury agreed with Ravgen that Austin-based Natera’s Panorama prenatal screening tests violate Ravgen’s patent rights in cell-free DNA testing technology,” Natera said in a statement that the award was “significantly less than the $410 million Ravgen was seeking.”